We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current WXIBF market cap is 6.34B. The company's latest EPS is CNY 0.7984 and P/E is 1.87.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 3.98B | 5.61B | 10.29B | 15.27B | 17.03B |
| Operating Income | 1.07B | 1.77B | 3.47B | 4.8B | 4.4B |
| Net Income | 1.01B | 1.69B | 3.39B | 4.42B | 3.4B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 17.6B | 28.96B | 44.03B | 49.56B | 56.58B |
| Total Liabilities | 4.71B | 8.06B | 11.33B | 13.35B | 12.56B |
| Total Equity | 12.9B | 20.9B | 32.71B | 36.21B | 44.02B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | 1.21B | 1.88B | 3.43B | 5.54B | 4.67B |
| Investing | -4.49B | -7.22B | -9.6B | -5.91B | -3.23B |
| Financing | 5.41B | 6.57B | 8.21B | -2.59B | 1.96B |
| Market Cap | 6.34B |
| Price to Earnings Ratio | 1.87 |
| Price to Sales Ratio | 0.37 |
| Price to Cash Ratio | 0.66 |
| Price to Book Ratio | 0.14 |
| Dividend Yield | - |
| Shares Outstanding | 4.26B |
| Average Volume (1 week) | 59.5k |
| Average Volume (1 Month) | 19.73k |
| 52 Week Change | -75.57% |
| 52 Week High | 6.60 |
| 52 Week Low | 1.416 |
| Spread (Intraday) | 0.25 (15.82%) |
| Company Name | Wuxi Biologics Cayman Inc (PK) |
| Address |
po box 309 grand cayman KY1-1104 |
| Website | https://www.wuxibiologics.com.cn |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
